テルイ ヤスヒト
TERUI Yasuhito
照井 康仁 所属 埼玉医科大学 医学部 血液内科 職種 教授 |
|
論文種別 | 学術雑誌(原著) |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2) |
掲載誌名 | 正式名:Support Care Cancer ISSNコード:14337339 |
掲載区分 | 国外 |
巻・号・頁 | 28,571-579頁 |
著者・共著者 | Yokoyama, M., Kusano, Y., Nishihara, A., Inoue, N., Nishimura, N., Mishima, Y., Terui, Y., Nukada, T., Nomura, T., Hatake, K. |
発行年月 | 2020 |
概要 | Data on Japanese patients were lacking; thus, we previously determined the incidence of FN in B-NHL patients at our center. Here, we aimed to gain additional insights into pegfilgrastim use in this population.|This single-center, retrospective, observational study (STOP FN in NHL 2) enrolled patients with B-NHL who underwent a regimen comprising rituximab and CHOP therapy over a 2-year period. The incidence of FN in cycle 1 of chemotherapy, risk factors for FN development, and use of daily G-CSF and pegfilgrastim were evaluated.|We evaluated 239 patients: 61 patients did not receive G-CSF and 178 received G-CSF. The incidence of FN was 10.5% in cycle 1 and 13.0% in all cycles. The FN incidence was significantly lower in patients receiving daily G-CSF and pegfilgrastim than patients not receiving G-CSF. Significant risk factors for FN were age ≥ 65 years, albumin < 3.5 g/dL, hemoglobin < 12 g/dL, and no prophylaxis with daily G-CSF/pegfilgrastim during cycle 1. |
DOI | 10.1007/s00520-019-04802-4 |
文献番号 | 31093770 |